

NHL	Vendor Name	Gender	Age	Histology subtype	Grade	positive Marker's	Site
NHL17001	530-A992	M	75	Mantle cell lymphoma (MCL)	typical not aggressive	CD19, CD20, CD5, CYCLIN-D+	Left Groin
NHL17002	530-A993	F	55	Follicular lymphoma (FL)	1	CD20, CD10, BCL2	Left level III
NHL17003	850-8104	M	63	Follicular lymphoma (FL)	1-2 of 3	BCL-1, BCL-2, BCL-6, CD3, CD5, CD10, CD20, CD21, CD43, PAX5	Right arm (soft tissue mass)
NHL17004	310-E799	M	62	Follicular lymphoma (FL)	not described	CD3, CD5, CD10, CD15, CD20, CD30, CD45, Pax-5, Ki-67	Right level II mass, Right posterior mass (excision)
NHL17005	850-8327	F	33	Diffuse large B-cell lymphoma (DLBCL)	High grade large B cell lymphoma	BCL1, BCL2, BCL6, CD3, CD20, C-MYC, CD30, MUM-1	Mediastinal Mass

Fig. 1




FIG. 2




FIG. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8

TIL type		L150	
		4hrs	24hrs
Metastatic TIL	TIL 1	5	ND
	TIL 2	40.5	ND
	TIL 3	75	ND
	TIL 4	80	ND
	TIL 5	106	ND
	TIL 6	115	ND
	TIL 7	175	ND
Lymphoma TIL	TIL 70611	6	27
	TIL 70612	20	7
	TIL 70613	20	20
	TIL 70614	2	20
	TIL 8036115	1	14

5
15
25




FIG. 10




Fig. 11




FIG. 12





FIG. 13



၇၇၃




FIG. 15

FIG. 16A




FIG. 16B




FIG. 16C





FIG. 16D







FIG. 18A




FIG. 18B




FIG. 19A





FIG. 19B






FIG. 20A




FIG. 20B




FIG. 20C




FIG. 20D





FIG. 21



229

FIG. 23

Process 2A: about 22 days from Steps A - E

1. STEP A

Obtain Patient Tumor Sample

2. STEP B

Fragmentation and First Expansion

3 days to 14 days

3. STEP C

First Expansion to Second Expansion Transition

No Storage and Closed System

4. STEP D

Second Expansion

IL-2, OKT-3, and antigen-presenting feeder cells

Closed System

5. STEP E

Harvest TILs from Step D

Closed System

6. STEP F

Final Formulation and/or Transfer to Infusion Bag

(optionally cryopreserve)

FIG. 24A

Method 1




FIG. 24B

Method 2




FIG. 24C




FIG. 25A





FIG. 25B






FIG. 26





FIG. 27






FIG. 28





FIG. 29D




FIG. 30B







FIG. 30D






FIG. 32A

CD28 subsets





FIG. 32B

CD28 subsets







FIG. 34B





FIG. 34A






FIG. 35B




FIG. 35A

FIG. 36A




FIG. 36B







FIG. 37A













FIG. 40A




FIG. 40B




FIG. 40C









FIG. 40D








FIG. 43B




FIG. 44B




FIG. 43A









FIG. 44A





Timeline - CLL PBL expansion process




FIG. 47

Timeline - AML MIL expansion process




FIG. 48